End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 EUR | -.--% | +8.31% | -.--% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 1.53M | - | ||
-14.96% | 11.13B | A- | ||
+69.37% | 3.6B | D+ | ||
-28.72% | 2.26B | C | ||
-14.31% | 2.16B | - | B- | |
-24.43% | 1.54B | C+ | ||
+37.25% | 1.17B | B- | ||
-3.28% | 744M | C+ | ||
-37.35% | 432M | C- | ||
+17.30% | 357M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- ECX Stock
- ECX Stock
- Ratings Epigenomics AG